BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory a review of the campaign by Veil and Kent (2008), they breakdown the message of the campaign utilizing the basic concepts of inoculation theory. They theorize that Johnson & Johnson used inoculation to alter the negative perception of their product. The campaign began running prior to the actual verdict, thus the timing seemed suspicious. A primary contention made by Veil and Kent (2008) was that the intentions of Johnson & Johnson were not to convey safety guidelines for consumers, but to change how the consumer might respond to further lawsuits on overdose. The inoculation strategy used by Johnson & Johnson,